Atreca, Inc., Licenses Transformational “Immune Repertoire Capture” Technology from Stanford University

--Proprietary approach will accelerate the discovery and development of novel therapeutic antibodies and vaccines--

Atreca, Inc., Licenses Transformational “Immune Repertoire Capture” Technology from Stanford University

<0> Company:Atreca, Inc.Paulette DillonChief Business Officer1-650-595-2661orMedia:Michele Parisi1-925-429-1850 </0>

Atreca, Inc., today announced that Stanford University has granted the company an exclusive license to transformational technology for harnessing the power of the immune response to generate a wide range of medical products.

“This unique approach rapidly identifies the repertoire of functional antibodies generated in an effective immune response, which until now has been an intractable challenge,” said Tito A. Serafini, Ph.D., chief executive officer, chief scientific officer, and co-founder of Atreca, Inc. “Atreca will apply these capabilities across a broad range of applications.”

The immune repertoire capture technology was developed in the laboratories of William H. Robinson, M.D., Ph.D., Associate Professor of Medicine in the Division of Immunology and Rheumatology at Stanford University.

“It has been an amazing journey,” said Dr. Robinson, a co-founder of Atreca. “Immune repertoire capture, which leverages next-generation sequencing, identifies new antibodies that have utility themselves and that define the targets of functional immune responses. The technology is therefore a highly prolific engine for the discovery and development of therapeutic antibodies, vaccines, diagnostics, and research reagents.”

"What impresses me about this technology is its extremely rapid throughput and comprehensive output," said Lawrence Steinman, M.D., the George A. Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University, and a co-founder of Atreca. “This is a game-changing technology that will bring us closer to more effective medicines and vaccines.”

Other co-founders of Atreca include Stanford researchers Robert Axtell, Ph.D., Jeremy Sokolove, M.D. (also an inventor), and Yann Chong Tan, Ph.D., (also an inventor); Guy Cavet, Ph.D.; and members of the Atreca management team Paulette Dillon, Daniel Emerling, Ph.D., Wayne Volkmuth, Ph.D., and Jonathan Woo, Ph.D.

Atreca has received initial funding from investors including Mission Bay Capital, whose team has deep collective experience investing in and building companies.

“Atreca is an early-stage technology company with great potential," said Douglas Crawford, Ph.D., Managing Partner, Mission Bay Capital, and Associate Director of the California Institute for Quantitative Biosciences (QB3). "Our investment will help Atreca commercialize this disruptive technology and rapidly identify new medicines to address significant patient need.”

Atreca, Inc., is a privately held biopharmaceutical company with an immune repertoire capture technology that revolutionizes the discovery and development of a wide range of products.

The Company was founded in 2010 and has its headquarters in San Carlos, California. For additional information, please visit: .

Suggested Articles

IMV’s lead immunotherapy stopped ovarian cancer from getting worse in more than three-quarters of patients in a small phase 2 study.

The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test with Roche’s checkpoint inhibitor Tecentriq.

Bicycle will apply its discovery platform to multiple targets, putting itself in a position to pull in up to $1.7 billion in milestones.